Saturday, October 10, 2026
BTC $83,015 ▲ 0.85%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
BTC$83,015up+0.85%ETH$2,516up+1.57%SOL$110.44up+1.57%XRP$1.41up+1.63%LINK$13.08up+2.46%ADA$0.253up+7.25%S&P 5007,812up+0.59%Nasdaq27,366up+0.64%Dow51,655up+0.83%RUT2,807up+0.46%TNX5.24%up+0.25%TYX5.60%down−0.11%FVX5.02%up+0.60%IRX4.06%up+0.35%VIX14.84down−3.70%GOLD$4,216.30up+1.43%SILVER$61.05up+2.73%OIL$91.85up+0.39%DXY102.23up+0.02%NVDA$229.28down−0.52%AAPL$336.64down−1.11%TSLA$382.70up+2.05%META$718.67down−0.31%MSFT$535.07up+2.38%AMZN$262.43up+3.29%GOOGL$351.66up+0.97%Fear & Greed64 — GreedBTC$83,015up+0.85%ETH$2,516up+1.57%SOL$110.44up+1.57%XRP$1.41up+1.63%LINK$13.08up+2.46%ADA$0.253up+7.25%S&P 5007,812up+0.59%Nasdaq27,366up+0.64%Dow51,655up+0.83%RUT2,807up+0.46%TNX5.24%up+0.25%TYX5.60%down−0.11%FVX5.02%up+0.60%IRX4.06%up+0.35%VIX14.84down−3.70%GOLD$4,216.30up+1.43%SILVER$61.05up+2.73%OIL$91.85up+0.39%DXY102.23up+0.02%NVDA$229.28down−0.52%AAPL$336.64down−1.11%TSLA$382.70up+2.05%META$718.67down−0.31%MSFT$535.07up+2.38%AMZN$262.43up+3.29%GOOGL$351.66up+0.97%Fear & Greed64 — Greed
Tag

viking therapeutics

1 article

Viking's Oral VK2735 Hits a Tolerability Wall; Injectable Offers the Real Upside
U.S. Equities2h ago
Viking's Oral VK2735 Hits a Tolerability Wall; Injectable Offers the Real Upside
VKTX's oral weight-loss candidate shows efficacy but high discontinuation rates in Phase 2 trials. The injectable formulation is where the value lies heading into 2027 Phase 3 readout.